Distribution and in vitro antifungal susceptibilities to caspofungin of Candida species isolated from critical ill patients

Abstract

Abstract:

Objective To investigate the distribution and in vitro activity of isolates of Candida from critical ill patients of general intensive care unit (ICU), aiming to guide the selection of antifungal. Methods All Candida isolates were taken from adult critical ill patients of general ICU from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, with ICU stay more than 3 days during February 2015 between February 2016 were identified and then tested for susceptibility to caspofungin using the CLSI M27-A3 broth microdilution method. Results 76 isolates of Candida were collected. 37 isolates of Candida spp, accounted for 48.7%, 20 isolates of C. tropicalis (26.3%), 8 isolates of C. glabrata and 8 isolates of C. parapsilosis (10.5%). 1 isolates of C.krusei, C.guilliermondii and C.lusitaniae each. Candida spp. remains high susceptibility to caspofungin (94.7%) in general ICU from Sun Yat-sen Memorial Hospital, Sun Yat-sen University. Resistance was found in 1 C.glabrata isolate, intermediate were found in 2 C.glabrata isolates and 1 C.albicans isolate. Conclusions C. albicans was the most commonly species among critical ill patients of general ICU from Sun Yat-sen Memorial Hospital, Sun Yat-sen University. The most frequently identified species of non-C.albicans is C.tropicalis. Most Candida spp. isolates remain high susceptibility to caspofungin in critical ill patients.

Key words: critically ill patient, caspofungin, invasive fungal disease, resistance of fungi

CLC Number:

R519.3

LI Fang-yi, ZHANG Jing, ZOU Zi-jun, YI Xiu-wen, LI Wei-chao, ZHOU Lin, ZHENG Yu-kai, HE Zhi-Jie. Distribution and in vitro antifungal susceptibilities to caspofungin of Candida species isolated from critical ill patients[J]. Chinese Journal of Mycology, 2018, 13(1): 20-23.

References

[1] Yapar N. Epidemiology and risk factors for invasive candidiasis[J]. Ther Clin Risk Manag, 2014, 10(95):105.
[2] Calandra T, Roberts JA, Antonelli M, et al. Diagnosis and management of invasive candidiasis in the ICU:an updated approach to an old enemy[J]. Crit Care, 2016, 20(1):125.
[3] Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained:a potential risk factor for hospital mortality[J]. Antimicrob Agents Chemother, 2005, 49(9):3640-3645.
[4] Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis:2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2015, 62(4):e1-50.
[5] Pfaller M, Boyken L, Hollis R, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin:six years of global surveillance[J]. J Clin Microbiol, 2008, 46(1):150-156.
[6] Pfaller MA, Castanheira M, Messer SA, et al. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents:data from the SENTRY antifungal surveillance program, 2010 through 2012[J]. Mycoses, 2015, 58(4):209-214.
[7] Kullberg BJ, Arendrup MC. Invasive candidiasis[J]. N Engl J Med, 2015, 373(15):1445-1456.
[8] Guo F, Yang Y, Kang Y, et al. Invasive candidiasis in intensive care units in China:a multicentre prospective observational study[J]. J Antimicrob Chemother, 2013, 68(7):1660-1668.
[9] Wang H, Xiao M, Chen SC, et al. In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study[J]. J Clin Microbiol, 2012, 50(12):3952-3959.
[10] Yesudhason BL, Mohanram K. Candida tropicalis as a predominant isolate from clinical specimens and its antifungal susceptibility pattern in a tertiary care hospital in Southern India[J]. J Clin Diagn Res, 2015, 9(7):DC14-16.
[11] Tan BH, Chakrabarti A, Li RY, et al. Incidence and species distribution of candidaemia in Asia:a laboratory-based surveillance study[J]. Clin Microbiol Infect, 2015, 21(10):946-953.
[12] Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in Candida glabrata:clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations[J]. Clin Infect Dis, 2013, 56(12):1724-1732.
[13] Arendrup MC, Perlin DS. Echinocandin resistance:an emerging clinical problem[J]. Curr Opin Infect Dis, 2014, 27(6):484-492.
[14] Perlin DS. Echinocandin resistance in Candida[J]. Clin Infect Dis, 2015, 61(suppl 6):S612-S617.
[15] Vallabhaneni S, Cleveland AA, Farley MM, et al. Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstream infections:data from a large multisite population-based candidemia surveillance program, 2008-2014[C]. Open Forum Infect Dis, 2015, 2
[4]:ofv163.
[16] Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Drug-resistant Candida glabrata infection in cancer patients[J]. Emerg Infect Dis, 2014, 20(11):1833-1840.
[17] Fothergill AW, Mccarthy DI, Albataineh MT, et al. Effects of treated versus untreated polystyrene on caspofungin in vitro activity against Candida species[J]. J Clin Microbiol, 2016, 54(3):734-738.